Adial Pharmaceuticals, Inc.
Moat Score — Adial Pharmaceuticals, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Adial holds patents around its genotype-targeted, low-dose ondansetron formulation (AD04) for Alcohol Use Disorder, which provides some intellectual property protection, but the company has no approved product, no brand recognition, and no regulatory exclusivity yet earned. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage company with no manufacturing or commercial scale, Adial has no cost advantage; it is a net cash consumer funded by dilutive equity raises. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no marketed product, Adial has no pricing power today; any future pricing power would depend entirely on clinical differentiation being validated and payer acceptance of a companion-diagnostic-gated therapy. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Adial's business model; a genetically-targeted small-molecule therapeutic does not benefit from user or data network dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because AUD is largely untreated pharmacologically today, there is little incumbent therapy for patients to switch away from, which lowers switching costs but also means Adial must create new prescribing behavior rather than displace an entrenched competitor. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The overall AUD pharmacotherapy market is a niche within psychiatry/addiction medicine, and Adial's genotype-defined subgroup is narrower still, which could support efficient scale for a focused specialty player if approved, but this remains hypothetical pre-approval. |